Foghorn Therapeutics’ (FHTX) Outperform Rating Reiterated at Wedbush

Chronological Source Flow
Back

AI Fusion Summary

Wedbush, BTIG, Jefferies, and Wall Street Zen have all upgraded Foghorn Therapeutics (FHTX) to buy/outperform, citing a $10‑12 target price range, reflecting bullish sentiment amid growing interest in its biotech pipeline.
#Foghorn Therapeutics #FHTX #Wedbush #BTIG #Jefferies #Wall Street Zen #buy rating #target price
15/03 08:38 defenseworld.net
3 Πηγές

Foghorn Therapeutics’ (FHTX) Outperform Rating Reiterated at Wedbush

Foghorn TherapeuticsFHTXWedbushBTIGJefferiesWall Street Zen
15/03 08:40 defenseworld.net

Wedbush Reaffirms Outperform Rating for Oruka Therapeutics (NASDAQ:ORKA)

ΠΟΛΙΤΙΚΗANALYST ARTICLES - USCOMPANIES
15/03 10:02 defenseworld.net

BTIG Research Reaffirms “Buy” Rating for Oruka Therapeutics (NASDAQ:ORKA)

ΠΟΛΙΤΙΚΗANALYST ARTICLES - USCOMPANIES
Comments
Loading...
0